Please login to the form below

Not currently logged in
Email:
Password:

US Department of Justice

This page shows the latest US Department of Justice news and features for those working in and with pharma, biotech and healthcare.

Purdue to pay over $8bn to settle opioid-related criminal claims

Purdue to pay over $8bn to settle opioid-related criminal claims

Purdue Pharma has reached an $8m+ settlement with the US Department of Justice to avoid federal civil and criminal charges related to claims it helped fuel the country’s opioid epidemic. ... today’s announcement re-affirms that the Department of

Latest news

  • US charges Teva for generic drug price-fixing plot US charges Teva for generic drug price-fixing plot

    Company maintains it has not committed any wrongdoing. The US Department of Justice (DoJ) has charged Teva Pharmaceuticals for conspiring with competitors in a generic drugs price-fixing probe. ... In May last year, a wide-ranging lawsuit was filed in

  • Ex-Sandoz exec admits role in generic drug price-fixing plot Ex-Sandoz exec admits role in generic drug price-fixing plot

    Reignites criticism of high drug prices in the US. Former Sandoz executive Hector Armando Kellum has pled guilty to charges levied against him, which allege he participated in a price-fixing ... Although these two medicines were the only ones

  • Teva among generic drugmakers hoping to settle US antitrust probe Teva among generic drugmakers hoping to settle US antitrust probe

    Teva Pharmaceuticals is among one of a number of generic drugmakers allegedly looking to resolve a criminal antitrust probe initiated by the US Department of Justice, according to Bloomberg. ... Back in  August, US politicians also accused Teva,

  • Avanir’s week goes from bad to worse with Alzheimer’s stumble Avanir’s week goes from bad to worse with Alzheimer’s stumble

    The US Department of Justice said on Friday that Avanir had encouraged prescribing of Nuedexta for unapproved uses, including agitation in AD, and took advantage of a drive to reduce the ... Otsuka paid $3.5bn to  acquire Avanir in 2014 as part of a

  • Reckitt hammered by $1.4bn opioid settlement bill Reckitt hammered by $1.4bn opioid settlement bill

    The settlement is the largest recovery for opioid drug mis-marketing in US history, according to the Department of Justice, and is made up of $647m to the federal government, $700m ... to an epidemic of overdose deaths across the US in the last few years.

More from news
Approximately 4 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    As prices in the US continue to spiral out of control, we can only look on with envy. ... Department of Justice.

  • As the opioid crisis grabs the headlines, the search for safe treatments continues As the opioid crisis grabs the headlines, the search for safe treatments continues

    Its share price took a massive hit when it was indicted by the US Justice Department earlier this year over its Suboxone Film therapy for opioid and heroin addiction, but its ... Pipeline provides hope. Indivior is fighting the Department of Justice

  • Cybersecurity Cybersecurity

    Generally the draft Regulation will not change this approach. One method of seeking to meet the adequacy requirement when transferring personal data to the US (which is not an approved country ... test). Following the decision in the Schrems case last

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....